Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Results 1-25 of 77 for your search:
Start Over
Transurethral Resection of Bladder Tumors Using PK Button Vaporization Electrode or Monopolar Loop Electrocautery in Treating Patients with Bladder Cancer
Phase: Phase IV
Type: Treatment
Age: 18 to 89
Trial IDs: WCI2119-11, NCI-2013-00065, IRB00053735, NCT01567462
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665
Goal-Directed Fluid Management or Standard Fluid Therapy in Reducing Delayed Bowel Function in Patients with Bladder Cancer Undergoing Surgery
Phase: Phase III
Type: Supportive care
Age: 21 and over
Trial IDs: 14-069, NCI-2014-01262, NCT02145871
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-045, NCI-2014-02598, 2014-002009-40, NCT02256436
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG-S1316, NCT02270450
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29294, NCI-2015-00200, 2014-003231-19, NCT02302807
Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-75, NCI-2009-00170, CDR0000492014, 7435, CCC-PHII-75, NCI-7435, NCT00365157
Everolimus and Gemcitabine Hydrochloride in Treating Patients With Refractory Primary or Secondary In Situ Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-165, NCI-2010-02341, NCT01259063
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-801-01-10, NCI-2011-03474, NCT01326871
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-801-01-12, NCI-2013-00693, NCT01625260
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HS410-101, NCI-2014-01420, NCT02010203
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG-naive Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Radiation Therapy and Cisplatin or Mitomycin and Fluorouracil in Treating Patients with Non-Muscle Invasive Stage I Bladder Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0926, NCI-2011-01974, 13-C-0175, CDR0000654727, PRTOG-0926_A05PAMDREVW01, NCT00981656
Pazopanib Hydrochloride and Paclitaxel in Treating Patients with Refractory Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BLDR0010, NCI-2011-00416, SU-04152010-5683, NCT01108055
Everolimus With or Without Paclitaxel as First-Line Therapy in Treating Patients Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-147, NCI-2013-00308, 1008-13, 1011004329, NCT01215136
Tesetaxel for Previously Treated Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TOBL204, NCI-2011-02438, NCT01215877
Gemcitabine Hydrochloride and Cisplatin in Treating Patients With High-Grade Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Biological Therapy in Improving Immune Reconstitution after Chemotherapy in Older Patients with Stage I-III Breast, Stage II Bladder, or Stage II-III Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 11-C-0146, NCI-2013-01487, 110146, P09590, NCT01339000
Gemcitabine Hydrochloride, Cisplatin, and Ipilimumab as First-Line Therapy in Treating Patients With Metastatic Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-148, NCI-2013-00250, 1110007307, NCT01524991
Dose Dense Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Muscle-Invasive Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-071, NCI-2012-00649, NCT01589094
Start Over